Epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40,000 I-Claim
U I-Claim
qw I-Claim
is I-Claim
effective I-Claim
in I-Claim
improving I-Claim
QOL I-Claim
, I-Claim
maintaining I-Claim
hemoglobin I-Claim
level I-Claim
, I-Claim
and I-Claim
reducing I-Claim
transfusion I-Claim
requirements I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Greater O
levels O
of O
anxiety O
, O
depression O
, O
and O
hostility O
at O
baseline O
were O
related O
to O
nausea O
and O
vomiting O
, O
quality O
of O
life O
, O
and O
perceived O
control O
over O
decision O
making O
. O

Using O
a O
computer-generated O
randomisation O
sequence O
, O
we O
randomly O
allocated O
patients O
to O
one O
of O
three O
groups O
( O
1:1:1 O
";" O
stratified O
by O
tumour O
site O
[ O
urological O
, O
gynaecological O
, O
or O
gastrointestinal O
] O
, O
and O
degree O
of O
bowel O
dysfunction O
[ O
IBDQ-B O
score O
< O
60 O
vs O
60-70 O
] O
) O
: O
usual O
care O
( O
a O
detailed O
self-help O
booklet O
) O
, O
gastroenterologist-led O
algorithm-based O
treatment O
, O
or O
nurse-led O
algorithm-based O
treatment O
. O

The O
EORTC O
24971/TAX O
323 O
, O
a O
phase O
III O
study O
of O
358 O
patients O
with O
unresectable O
locoregionally O
advanced O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
, O
showed O
an O
improved O
progression-free O
and O
overall O
survival O
( O
OS O
) O
with O
less O
toxicity O
when O
docetaxel O
( O
T O
) O
was O
added O
to O
cisplatin O
and O
5-fluorouracil O
( O
PF O
) O
for O
induction O
and O
given O
before O
radiotherapy O
( O
RT O
) O
. O

No B-Claim
substantive I-Claim
differences I-Claim
were I-Claim
detected I-Claim
between I-Claim
outcomes I-Claim
of I-Claim
embolization I-Claim
with I-Claim
PVA I-Claim
particles I-Claim
or I-Claim
tris-acryl I-Claim
gelatin I-Claim
microspheres I-Claim
. I-Claim

bolus O
( O
arm O
C O
) O
. O

One O
hundred O
fifty-three O
patients O
were O
randomly O
assigned O
to O
PLD O
( O
n O
= O
76 O
) O
or O
GEM O
( O
n O
= O
77 O
) O
. O

In B-Claim
vivo I-Claim
data I-Claim
have I-Claim
shown I-Claim
a I-Claim
more I-Claim
potent I-Claim
antiangiogenic I-Claim
effect I-Claim
and I-Claim
a I-Claim
higher I-Claim
antitumor I-Claim
activity I-Claim
of I-Claim
low-dose I-Claim
interferon I-Claim
( I-Claim
IFN I-Claim
) I-Claim
given I-Claim
twice I-Claim
daily I-Claim
. I-Claim

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
12 I-Premise
months I-Premise
and I-Premise
382 I-Premise
deaths I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
clear I-Premise
survival I-Premise
benefit I-Premise
when I-Premise
comparing I-Premise
PCV I-Premise
with I-Premise
TMZ I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.91 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.74 I-Premise
to I-Premise
1.11 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.350 I-Premise
) I-Premise
. I-Premise

A O
total O
of O
448 O
patients O
were O
enrolled O
over O
a O
period O
of O
3 O
years O
. O

Erlotinib B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
had I-Claim
no I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QoL I-Claim
in I-Claim
this I-Claim
subpopulation I-Claim
. I-Claim

Eligibility O
required O
that O
patients O
have O
grade O
1 O
or O
higher O
sensory O
neuropathy O
according O
to O
the O
NCI O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
and O
at O
least O
4 O
on O
a O
scale O
of O
0 O
to O
10 O
, O
representing O
average O
chemotherapy-induced O
pain O
, O
after O
paclitaxel O
, O
other O
taxane O
, O
or O
oxaliplatin O
treatment O
. O

SGN-15 O
is O
an O
antibody-drug O
conjugate O
( O
ADC O
) O
, O
consisting O
of O
a O
chimeric O
murine O
monoclonal O
antibody O
recognizing O
the O
Lewis O
Y O
( O
Le O
( O
y O
) O
) O
antigen O
, O
conjugated O
to O
doxorubicin O
. O

( O
600 O
mg/m O
( O
2 O
) O
day O
1-28 O
of O
a O
56-day O
cycle O
) O
for O
a O
maximum O
of O
12 O
cycles O
( O
i.v O
. O
) O

Patients O
randomized O
to O
combination O
therapy O
were O
given O
oral O
13-CRA O
1 O
mg/kg/d O
plus O
IFNalpha2a O
. O

This O
study O
aimed O
to O
compare O
quality O
of O
life O
( O
QOL O
) O
, O
functional O
outcome O
, O
body O
image O
, O
and O
cosmesis O
after O
hand-assisted O
laparoscopic O
( O
LRP O
) O
versus O
open O
restorative O
proctocolectomy O
( O
ORP O
) O
. O

They O
may O
have O
unmet O
needs O
after O
active O
treatment O
. O

Patients B-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
significantly I-Premise
more I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

This O
study O
took O
place O
at O
the O
Royal O
Prince O
Alfred O
Hospital O
, O
Sydney O
, O
Australia O
. O

We O
designed O
a O
trial O
to O
investigate O
the O
effects O
of O
epoetin O
alfa O
therapy O
on O
the O
QOL O
of O
anemic O
patients O
with O
advanced O
non-small-cell O
carcinoma O
of O
the O
lung O
( O
NSCLC O
) O
. O

A B-Claim
blinded I-Claim
RCT I-Claim
investigating I-Claim
the I-Claim
role I-Claim
of I-Claim
epidural I-Claim
and I-Claim
WIC I-Claim
administration I-Claim
for I-Claim
postoperative I-Claim
analgesia I-Claim
following I-Claim
LCR I-Claim
is I-Claim
feasible I-Claim
. I-Claim

A B-Claim
combination I-Claim
of I-Claim
mitoxantrone I-Claim
plus I-Claim
prednisone I-Claim
is I-Claim
preferable I-Claim
to I-Claim
prednisone I-Claim
alone I-Claim
for I-Claim
reduction I-Claim
of I-Claim
pain I-Claim
in I-Claim
men I-Claim
with I-Claim
metastatic I-Claim
, I-Claim
hormone-resistant I-Claim
, I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

All B-Claim
the I-Claim
three I-Claim
opioids I-Claim
used I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
were I-Claim
effective I-Claim
, I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
and I-Claim
required I-Claim
similar I-Claim
amounts I-Claim
of I-Claim
symptomatic I-Claim
drugs I-Claim
or I-Claim
co-analgesics I-Claim
. I-Claim

The O
Active O
After O
Cancer O
Trial O
( O
AACT O
) O
was O
a O
multicenter O
pilot O
study O
evaluating O
the O
feasibility O
of O
a O
telephone-based O
exercise O
intervention O
in O
a O
cooperative O
group O
setting O
. O

Supervised O
exercise O
, O
comprising O
high-intensity O
cardiovascular O
and O
heavy O
resistance O
training O
, O
relaxation- O
and O
body O
awareness O
training O
and O
massage O
, O
9 O
h O
weekly O
for O
6 O
weeks O
. O

A O
total O
of O
402 O
eligible O
patients O
were O
registered O
to O
step O
1 O
, O
and O
223 O
eligible O
patients O
were O
registered O
to O
step O
2 O
( O
observation O
, O
n O
= O
111 O
";" O
topotecan O
, O
n O
= O
112 O
) O
. O

Finally O
, O
black B-Premise
women I-Premise
and I-Premise
white I-Premise
women I-Premise
were I-Premise
similar I-Premise
in I-Premise
terms I-Premise
of I-Premise
how I-Premise
they I-Premise
benefited I-Premise
from I-Premise
the I-Premise
MBAT I-Premise
intervention I-Premise
, I-Premise
even I-Premise
though I-Premise
white I-Premise
participants I-Premise
tended I-Premise
to I-Premise
have I-Premise
higher I-Premise
educational I-Premise
level I-Premise
and I-Premise
marital I-Premise
status I-Premise
. I-Premise

Longitudinal O
data O
were O
available O
for O
166 O
Swedish O
men O
who O
had O
answered O
quality-of-life O
questionnaires O
at O
an O
earlier O
timepoint O
. O

Tamoxifen B-Claim
decreases I-Claim
the I-Claim
incidence I-Claim
of I-Claim
invasive I-Claim
and I-Claim
noninvasive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

There O
were O
70 O
female O
posttreatment O
anal O
or O
rectal O
cancer O
survivors O
assessed O
as O
part O
of O
the O
current O
study O
. O

Exploratory O
analyses O
were O
performed O
on O
a O
data O
set O
from O
a O
previous O
study O
. O

At B-Premise
12 I-Premise
months I-Premise
postradiotherapy I-Premise
, I-Premise
12 I-Premise
( I-Premise
50.0 I-Premise
% I-Premise
) I-Premise
and I-Premise
20 I-Premise
patients I-Premise
( I-Premise
83.3 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IMRT I-Premise
group I-Premise
had I-Premise
recovered I-Premise
at I-Premise
least I-Premise
25 I-Premise
% I-Premise
of I-Premise
preradiotherapy I-Premise
SWS I-Premise
and I-Premise
SPS I-Premise
flow I-Premise
respectively I-Premise
, I-Premise
compared I-Premise
with I-Premise
1 I-Premise
( I-Premise
4.8 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
patients I-Premise
( I-Premise
9.5 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
the I-Premise
CRT I-Premise
group I-Premise
. I-Premise

Assessments O
at O
baseline O
, O
one O
, O
three O
, O
and O
6 O
months O
included O
barriers O
, O
the O
Brief O
Pain O
Inventory O
, O
opioid O
use O
, O
and O
physician O
and O
nurse O
ratings O
of O
their O
patients O
' O
pain O
. O

In B-Claim
the I-Claim
radical I-Claim
prostatectomy I-Claim
group I-Claim
, I-Claim
erectile I-Claim
dysfunction I-Claim
and I-Claim
urinary I-Claim
leakage I-Claim
were I-Claim
often I-Claim
consequences I-Claim
of I-Claim
surgery I-Claim
. I-Claim

Research B-Claim
is I-Claim
needed I-Claim
to I-Claim
assess I-Claim
the I-Claim
long I-Claim
term I-Claim
risks I-Claim
and I-Claim
benefits I-Claim
of I-Claim
starting I-Claim
hormone I-Claim
replacement I-Claim
therapy I-Claim
near I-Claim
the I-Claim
menopause I-Claim
, I-Claim
when I-Claim
the I-Claim
effect I-Claim
may I-Claim
be I-Claim
different I-Claim
. I-Claim

The O
primary O
endpoint O
was O
the O
difference O
in O
proportion O
of O
patients O
with O
ARSR O
, O
assessed O
with O
the O
Radiation O
Therapy O
Oncology O
Group/The O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Acute O
Radiation O
Morbidity O
Scoring O
Criteria O
( O
RTOG/EORTC O
scale O
) O
at O
follow-up O
. O

The O
Southwest O
Oncology O
Group O
( O
SWOG O
) O
intergroup O
trial O
compared O
radical O
prostatectomy O
( O
RP O
) O
plus O
observation O
versus O
RP O
plus O
adjuvant O
radiation O
therapy O
( O
RT O
) O
. O

Behavioral O
symptoms O
are O
common O
in O
breast O
cancer O
survivors O
, O
including O
disturbances O
in O
energy O
, O
sleep O
, O
and O
mood O
, O
though O
few O
risk O
factors O
for O
these O
negative O
outcomes O
have O
been O
identified O
. O

However B-Claim
, I-Claim
the I-Claim
overall I-Claim
survival I-Claim
was I-Claim
similar I-Claim
suggesting I-Claim
that I-Claim
alternating I-Claim
bolus I-Claim
and I-Claim
infusional I-Claim
5-FU I-Claim
upfront I-Claim
may I-Claim
be I-Claim
as I-Claim
effective I-Claim
as I-Claim
giving I-Claim
them I-Claim
in I-Claim
sequence I-Claim
as I-Claim
first- I-Claim
and I-Claim
second-line I-Claim
treatment I-Claim
. I-Claim

Eligible O
patients O
who O
had O
previously O
completed O
four O
cycles O
of O
platinum-based O
chemotherapy O
were O
randomised O
1:1 O
to O
receive O
erlotinib O
150 O
mg/day O
or O
placebo O
until O
disease O
progression O
, O
unacceptable O
toxicity O
or O
death O
. O

Exemestane B-Premise
patients I-Premise
reported I-Premise
more I-Premise
bone/muscle I-Premise
aches I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
P I-Premise
= I-Premise
.0004 I-Premise
) I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
sleeping I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

The B-Premise
QLQ-C30 I-Premise
subscales I-Premise
physical I-Premise
function I-Premise
( I-Premise
P=0.044 I-Premise
) I-Premise
and I-Premise
constipation I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
during I-Premise
induction I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
MP I-Premise
arm I-Premise
. I-Premise

From O
1984 O
to O
1989 O
, O
the O
Swiss O
Group O
for O
Clinical O
Cancer O
Research O
( O
SAKK O
) O
performed O
a O
randomized O
phase O
III O
trial O
comparing O
early O
versus O
late O
alternating O
chemotherapy O
in O
patients O
with O
small-cell O
lung O
cancer O
. O

Evidence B-Claim
suggests I-Claim
that I-Claim
the I-Claim
re-entry I-Claim
phase I-Claim
( I-Claim
ie I-Claim
, I-Claim
early I-Claim
period I-Claim
after I-Claim
medical I-Claim
treatment I-Claim
completion I-Claim
) I-Claim
presents I-Claim
distinct I-Claim
challenges I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Response O
was O
evaluated O
4 O
weeks O
after O
the O
last O
cycle O
. O

Toxicity B-Premise
was I-Premise
generally I-Premise
limited I-Premise
to I-Premise
musculoskeletal I-Premise
symptoms I-Premise
( I-Premise
18 I-Premise
% I-Premise
grade I-Premise
3/4 I-Premise
for I-Premise
marimastat I-Premise
) I-Premise
. I-Premise

Patients O
with O
progressive O
, O
androgen-independent O
prostate O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
either O
ketoconazole/doxorubicin O
alternating O
with O
vinblastine/estramustine O
( O
KA/VE O
) O
or O
paclitaxel O
, O
estramustine O
, O
and O
oral O
etoposide O
( O
TEE O
) O
. O

HRQOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Core O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
EORTC O
Lung O
Cancer O
Module O
( O
QLQ-LC13 O
) O
tools O
. O

Incorporation B-Claim
of I-Claim
docetaxel I-Claim
, I-Claim
as I-Claim
in I-Claim
DCF I-Claim
or I-Claim
with I-Claim
other I-Claim
active I-Claim
drug I-Claim
( I-Claim
s I-Claim
) I-Claim
, I-Claim
is I-Claim
a I-Claim
new I-Claim
therapy I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
untreated I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
. I-Claim

Seventy-six O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
-associated O
Kaposi O
sarcoma O
were O
randomized O
to O
receive O
the O
study O
drug O
either O
once O
( O
n O
= O
30 O
) O
or O
3 O
times O
weekly O
( O
n O
= O
46 O
) O
. O

Planned O
subgroup O
analyses O
were O
also O
conducted O
. O

Patients O
completed O
the O
SWOG O
Quality O
of O
Life O
Questionnaire O
( O
emotional O
, O
physical O
, O
social O
, O
and O
role O
function O
";" O
general O
symptom O
status O
";" O
treatment/disease-specific O
symptoms O
";" O
and O
global O
HRQL O
[ O
GHRQL O
] O
) O
at O
baseline O
, O
6 O
weeks O
, O
6 O
months O
, O
and O
annually O
for O
5 O
years O
. O

Time O
to O
definitive O
deterioration O
of O
QOL O
parameters O
was O
analyzed O
. O

Bootstrap O
simulations O
( O
10,000 O
iterations O
) O
were O
conducted O
to O
account O
for O
uncertainty O
, O
and O
sensitivity O
analyses O
were O
conducted O
to O
establish O
robustness O
. O

The O
study O
group O
joined O
a O
weekly O
session O
of O
ALT O
for O
3 O
months O
in O
addition O
to O
the O
self-management O
therapy O
. O

A B-Premise
significantly I-Premise
lower I-Premise
serum I-Premise
interleukin-6 I-Premise
level I-Premise
was I-Premise
found I-Premise
in I-Premise
comparing I-Premise
glutamine-enriched I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
but B-Premise
not I-Premise
in I-Premise
interleukin-10 I-Premise
( I-Premise
P I-Premise
= I-Premise
0.374 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
levels I-Premise
( I-Premise
P I-Premise
= I-Premise
0.653 I-Premise
) I-Premise
. I-Premise

The B-Premise
most I-Premise
frequent I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
grade I-Premise
3/4 I-Premise
diarrhea I-Premise
( I-Premise
arm I-Premise
A I-Premise
: I-Premise
34 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
, I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
( I-Premise
A I-Premise
: I-Premise
5 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
grade I-Premise
2/3 I-Premise
alopecia I-Premise
( I-Premise
A I-Premise
: I-Premise
26 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
65 I-Premise
% I-Premise
) I-Premise
. I-Premise

To O
determine O
the O
efficacy O
, O
impact O
on O
quality-of-life O
( O
QoL O
) O
and O
tolerability O
of O
two O
different O
irinotecan O
administration O
schedules O
in O
combination O
with O
capecitabine O
as O
first-line O
treatment O
of O
metastatic O
colorectal O
cancer O
. O

203 O
women O
entered O
the O
study O
";" O
177 O
completed O
the O
six O
month O
follow-up O
. O

However B-Premise
, I-Premise
complete I-Premise
gingival I-Premise
healing I-Premise
occurred I-Premise
in I-Premise
only I-Premise
14 I-Premise
of I-Premise
25 I-Premise
HBO-treated I-Premise
patients I-Premise
( I-Premise
52 I-Premise
% I-Premise
) I-Premise
versus I-Premise
7 I-Premise
of I-Premise
21 I-Premise
controls I-Premise
( I-Premise
33.3 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.203 I-Premise
, I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
healing I-Premise
was I-Premise
59 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
42.8 I-Premise
% I-Premise
to I-Premise
75.8 I-Premise
% I-Premise
) I-Premise
for I-Premise
HBO-treated I-Premise
patients I-Premise
versus I-Premise
70 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
CI I-Premise
, I-Premise
52.2 I-Premise
% I-Premise
to I-Premise
88.36 I-Premise
% I-Premise
) I-Premise
for I-Premise
controls I-Premise
( I-Premise
P I-Premise
= I-Premise
.32 I-Premise
, I-Premise
log-rank I-Premise
test I-Premise
) I-Premise
. I-Premise

Corresponding B-Premise
median I-Premise
failure-free I-Premise
survival I-Premise
times I-Premise
were I-Premise
3.1 I-Premise
and I-Premise
1.7 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.20 I-Premise
) I-Premise
. I-Premise

The O
general O
exercise O
group O
performed O
body O
conditioning O
exercise O
. O

The O
benefits O
of O
sertraline O
compared O
with O
placebo O
are O
expressed O
on O
a O
range O
from O
100 O
( O
ie O
, O
maximum O
benefit O
) O
to O
-100 O
( O
ie O
, O
maximum O
harm O
) O
";" O
a O
difference O
of O
10 O
was O
deemed O
clinically O
significant O
. O

In O
conclusion O
, O
TMX B-Claim
does I-Claim
not I-Claim
prolong I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
HCC I-Claim
and I-Claim
has I-Claim
an I-Claim
increasingly I-Claim
negative I-Claim
impact I-Claim
with I-Claim
increasing I-Claim
dose I-Claim
. I-Claim

The O
control O
group O
was O
instructed O
to O
perform O
the O
self-management O
treatment O
. O

Despite O
premature O
trial O
closure O
, O
our O
data O
provided O
valuable O
insights O
. O

The B-Premise
hazard I-Premise
ration I-Premise
( I-Premise
HR I-Premise
) I-Premise
for I-Premise
PFS I-Premise
was I-Premise
0.72 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.58 I-Premise
to I-Premise
0.90 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0031 I-Premise
) I-Premise
. I-Premise

406 O
eligible O
patients O
were O
entered O
into O
the O
trial O
. O

Global B-Premise
QL I-Premise
scores I-Premise
were I-Premise
lower I-Premise
at I-Premise
both I-Premise
1 I-Premise
and I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
for I-Premise
patients I-Premise
treated I-Premise
by I-Premise
SEMSs I-Premise
( I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
1=-0.66 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
-0.02 I-Premise
to I-Premise
-1.30 I-Premise
, I-Premise
P=0.04 I-Premise
";" I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
6=-1.01 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.30 I-Premise
to I-Premise
-1.72 I-Premise
, I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

The B-Claim
results I-Claim
of I-Claim
this I-Claim
brief I-Claim
pilot I-Claim
counseling I-Claim
intervention I-Claim
demonstrated I-Claim
significant I-Claim
gains I-Claim
in I-Claim
sexual I-Claim
function I-Claim
and I-Claim
satisfaction I-Claim
and I-Claim
increased I-Claim
utilization I-Claim
of I-Claim
treatments I-Claim
for I-Claim
ED I-Claim
. I-Claim

Patients O
( O
n O
= O
110 O
) O
with O
stage O
II O
, O
III O
, O
or O
IV O
breast O
cancer O
scheduled O
to O
receive O
high O
dose O
chemotherapy O
and O
autologous O
hematopoietic O
stem O
cell O
transplantation O
were O
randomized O
to O
either O
CCSP O
treatment O
or O
control O
group O
. O

In B-Claim
V325 I-Claim
, I-Claim
advanced I-Claim
gastric I-Claim
or I-Claim
gastroesophageal I-Claim
junction I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
DCF I-Claim
not I-Claim
only I-Claim
had I-Claim
statistically I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
and I-Claim
time I-Claim
to I-Claim
tumor-progression I-Claim
, I-Claim
but I-Claim
they I-Claim
also I-Claim
had I-Claim
better I-Claim
preservation I-Claim
of I-Claim
QOL I-Claim
compared I-Claim
with I-Claim
patients I-Claim
receiving I-Claim
CF I-Claim
. I-Claim

Concurrent O
validity O
of O
the O
mood O
linear O
analogue O
self-assessment O
was O
consistently O
confirmed O
across O
four O
language O
groups O
. O

QOL B-Claim
and I-Claim
sexual I-Claim
function I-Claim
are I-Claim
not I-Claim
negatively I-Claim
influenced I-Claim
by I-Claim
these I-Claim
2 I-Claim
treatment I-Claim
options I-Claim
. O

Researchers O
and O
outcome O
assessors O
were O
blinded O
for O
assigned O
treatment O
. O

In B-Claim
this I-Claim
, I-Claim
the I-Claim
first I-Claim
report I-Claim
of I-Claim
HRQoL I-Claim
over I-Claim
5 I-Claim
years I-Claim
of I-Claim
initial I-Claim
adjuvant I-Claim
therapy I-Claim
with I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
, I-Claim
we I-Claim
conclude I-Claim
that I-Claim
anastrozole I-Claim
and I-Claim
tamoxifen I-Claim
had I-Claim
similar I-Claim
impacts I-Claim
on I-Claim
HRQoL I-Claim
, I-Claim
which I-Claim
was I-Claim
maintained I-Claim
or I-Claim
slightly I-Claim
improved I-Claim
during I-Claim
the I-Claim
treatment I-Claim
period I-Claim
for I-Claim
both I-Claim
groups I-Claim
. I-Claim

Neither O
demographic O
nor O
medical O
variables O
explained O
this O
association O
. O

The O
change O
in O
the O
Glasgow O
Prognostic O
Score O
( O
GPS O
) O
during O
treatment O
was O
also O
assessed O
. O

To O
facilitate O
the O
transition O
to O
recovery O
, O
we O
conducted O
the O
Moving O
Beyond O
Cancer O
( O
MBC O
) O
trial O
, O
a O
multisite O
, O
randomized O
, O
controlled O
trial O
of O
psychoeducational O
interventions O
for O
breast O
cancer O
patients O
. O

No B-Premise
decrease I-Premise
in I-Premise
fatigue-related I-Premise
distress I-Premise
was I-Premise
detected I-Premise
. I-Premise

The B-Premise
overall I-Premise
remission I-Premise
rate I-Premise
was I-Premise
87 I-Premise
% I-Premise
with I-Premise
31 I-Premise
% I-Premise
complete I-Premise
remissions I-Premise
. I-Premise

The B-Premise
RR I-Premise
was I-Premise
70 I-Premise
% I-Premise
versus I-Premise
74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.3492 I-Premise
) I-Premise
. I-Premise

If B-Premise
offered I-Premise
a I-Premise
choice I-Premise
, I-Premise
80 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
prior I-Premise
to I-Premise
start I-Premise
and I-Premise
58 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
program I-Premise
indicated I-Premise
that I-Premise
they I-Premise
preferred I-Premise
the I-Premise
entire I-Premise
multidimensional I-Premise
program I-Premise
. I-Premise

Over B-Premise
subsequent I-Premise
assessments I-Premise
, I-Premise
HRQOL I-Premise
was I-Premise
much I-Premise
the I-Premise
same I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

1442 O
patients O
were O
registered O
for O
the O
trial O
, O
of O
whom O
529 O
were O
randomly O
assigned O
to O
treatment O
groups O
and O
were O
included O
in O
our O
analysis O
( O
265 O
early O
, O
264 O
delayed O
) O
. O

Baseline O
characteristics O
, O
including O
LCSS O
scores O
, O
were O
well O
balanced O
between O
groups O
. O

Eight O
hundred O
sixty-one O
patients O
were O
accrued O
from O
89 O
sites O
in O
16 O
countries O
. O

Methods B-Claim
are I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
professional I-Claim
time I-Claim
required I-Claim
while I-Claim
achieving I-Claim
sustained I-Claim
intervention I-Claim
effectiveness I-Claim
. I-Claim

Toxicity B-Premise
was I-Premise
acceptable I-Premise
, I-Premise
with I-Premise
one I-Premise
toxic I-Premise
death I-Premise
( I-Premise
TC I-Premise
arm I-Premise
) I-Premise
. I-Premise

The B-Claim
effect I-Claim
appeared I-Claim
to I-Claim
be I-Claim
dose-dependent I-Claim
. I-Claim

To O
assess O
whether O
the O
administration O
of O
recombinant O
human O
erythropoietin O
( O
r-HuEPO O
) O
would O
increase O
the O
hematocrit O
, O
reduce O
the O
requirement O
for O
transfusion O
, O
and O
improve O
the O
quality O
of O
life O
in O
anemic O
cancer O
patients O
receiving O
myelosuppressive O
, O
cisplatin-based O
chemotherapy O
. O

This O
international O
, O
randomized O
, O
controlled O
, O
multicenter O
trial O
aimed O
to O
compare O
the O
efficacy O
and O
safety O
of O
recombinant O
human O
TSH O
( O
rhTSH O
) O
to O
prepare O
euthyroid O
patients O
on O
L-thyroxine O
therapy O
( O
euthyroid O
group O
) O
to O
ablate O
remnant O
thyroid O
tissue O
with O
3.7 O
GBq O
( O
100 O
mCi O
) O
131I O
, O
compared O
with O
that O
with O
conventional O
remnant O
ablation O
performed O
in O
the O
hypothyroid O
state O
( O
hypothyroid O
group O
) O
. O

Severe B-Premise
HSRs I-Premise
were I-Premise
rare I-Premise
( I-Premise
1.5 I-Premise
% I-Premise
patients I-Premise
) I-Premise
and I-Premise
were I-Premise
not I-Premise
affected I-Premise
by I-Premise
either I-Premise
dose I-Premise
or I-Premise
schedule I-Premise
. I-Premise

However B-Claim
, I-Claim
further I-Claim
research I-Claim
is I-Claim
needed I-Claim
to I-Claim
identify I-Claim
ways I-Claim
to I-Claim
improve I-Claim
the I-Claim
potency I-Claim
and I-Claim
sustainability I-Claim
of I-Claim
psychoeducational I-Claim
interventions I-Claim
for I-Claim
managing I-Claim
cancer-related I-Claim
fatigue I-Claim
. I-Claim

The B-Premise
tumor I-Premise
progression I-Premise
duration I-Premise
in I-Premise
these I-Premise
two I-Premise
groups I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
5.6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The O
aim O
of O
this O
multicenter O
, O
double-blind O
, O
prospective O
, O
randomized O
trial O
was O
to O
evaluate O
the O
clinical O
efficacy O
of O
an O
economically O
viable O
antimicrobial O
lozenge O
( O
bacitracin O
, O
clotrimazole O
, O
and O
gentamicin O
[ O
BcoG O
] O
) O
in O
the O
alleviation O
of O
radiation-induced O
mucositis O
in O
patients O
with O
head O
and O
neck O
cancer O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
community I-Premise
locations I-Premise
in I-Premise
favour I-Premise
of I-Premise
home I-Premise
( I-Premise
+15·2 I-Premise
, I-Premise
1·3 I-Premise
to I-Premise
29·1 I-Premise
, I-Premise
P=0.033 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT-Anemia I-Premise
or I-Premise
ESAS I-Premise
instruments I-Premise
. I-Premise

Global B-Claim
quality I-Claim
of I-Claim
life I-Claim
did I-Claim
not I-Claim
differ I-Claim
within I-Claim
the I-Claim
three I-Claim
arms I-Claim
. I-Claim

Tumour-related O
symptoms O
were O
present O
in O
134 O
( O
71 O
% O
) O
patients O
and O
weight O
loss O
of O
more O
than O
5 O
% O
was O
seen O
in O
15 O
( O
8 O
% O
) O
patients O
. O

Rates B-Premise
of I-Premise
resource I-Premise
use I-Premise
were I-Premise
statistically I-Premise
higher I-Premise
for I-Premise
pemetrexed I-Premise
than I-Premise
for I-Premise
placebo I-Premise
: I-Premise
admissions I-Premise
to I-Premise
hospital I-Premise
for I-Premise
drug-related I-Premise
adverse I-Premise
events I-Premise
( I-Premise
19 I-Premise
[ I-Premise
4 I-Premise
% I-Premise
] I-Premise
vs I-Premise
none I-Premise
";" I-Premise
p=0·001 I-Premise
) I-Premise
, I-Premise
transfusions I-Premise
( I-Premise
42 I-Premise
[ I-Premise
10 I-Premise
% I-Premise
] I-Premise
vs I-Premise
seven I-Premise
[ I-Premise
3 I-Premise
% I-Premise
] I-Premise
";" I-Premise
p=0·003 I-Premise
) I-Premise
, I-Premise
and I-Premise
erythropoiesis-stimulating I-Premise
agents I-Premise
( I-Premise
26 I-Premise
[ I-Premise
6 I-Premise
% I-Premise
] I-Premise
vs I-Premise
four I-Premise
[ I-Premise
2 I-Premise
% I-Premise
] I-Premise
";" I-Premise
p=0·017 I-Premise
) I-Premise
. I-Premise

The B-Claim
-3 I-Claim
and I-Claim
5-year I-Claim
survival I-Claim
rates I-Claim
of I-Claim
nonsurgical I-Claim
therapy I-Claim
were I-Claim
comparable I-Claim
to I-Claim
published I-Claim
surgical I-Claim
trials I-Claim
of I-Claim
N2 I-Claim
disease I-Claim
. I-Claim

The O
aim O
of O
this O
prospective O
controlled O
study O
was O
to O
assess O
the O
efficacy O
of O
two O
different O
combination O
treatment O
modalities O
of O
lymphedema O
( O
LE O
) O
. O

In B-Premise
the I-Premise
expanded I-Premise
pattern-mixture I-Premise
model I-Premise
, I-Premise
EVE I-Premise
+ I-Premise
EXE-treated I-Premise
patients I-Premise
who I-Premise
did I-Premise
not I-Premise
drop I-Premise
out I-Premise
early I-Premise
had I-Premise
stable I-Premise
BRBS I-Premise
and I-Premise
BRAS I-Premise
relative I-Premise
to I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
. I-Premise

Of O
5,187 O
randomly O
assigned O
women O
in O
the O
trial O
, O
3,612 O
( O
69.9 O
% O
) O
participated O
in O
the O
QOL O
substudy O
: O
1,799 O
were O
allocated O
to O
placebo O
and O
1,813 O
were O
allocated O
to O
letrozole O
. O

The B-Premise
night I-Premise
awakenings I-Premise
( I-Premise
Actigraph I-Premise
) I-Premise
pattern I-Premise
was I-Premise
significantly I-Premise
different I-Premise
by I-Premise
group I-Premise
over I-Premise
time I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
between I-Premise
groups I-Premise
at I-Premise
90 I-Premise
days I-Premise
or I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

The O
primary O
outcomes O
were O
survival O
( O
PCV O
v O
TMZ O
) O
and O
12-week O
progression-free O
survival O
( O
PFS O
";" O
TMZ-5 O
v O
TMZ-21 O
) O
. O

Patients O
were O
randomly O
assigned O
to O
intervention O
( O
n O
= O
242 O
) O
or O
enhanced O
usual O
care O
( O
EUC O
";" O
n O
= O
230 O
) O
. O

Statistical O
tests O
were O
two-sided O
. O

However B-Claim
, I-Claim
modifications I-Claim
are I-Claim
needed I-Claim
in I-Claim
future I-Claim
randomized I-Claim
trials I-Claim
to I-Claim
reduce I-Claim
the I-Claim
rate I-Claim
of I-Claim
premature I-Claim
termination I-Claim
and I-Claim
to I-Claim
improve I-Claim
long-term I-Claim
maintenance I-Claim
of I-Claim
gains I-Claim
. I-Claim

Hazard O
ratios O
( O
HRs O
) O
for O
comparing O
thalidomide O
against O
placebo O
were O
estimated O
using O
Cox O
regression O
modeling O
. O

Dermatology B-Premise
Life I-Premise
Quality I-Premise
Index I-Premise
( I-Premise
DLQI I-Premise
) I-Premise
scores I-Premise
were I-Premise
assessed I-Premise
for I-Premise
each I-Premise
treatment I-Premise
modality I-Premise
at I-Premise
week I-Premise
4 I-Premise
and I-Premise
were I-Premise
1.95 I-Premise
and I-Premise
1.38 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
.20 I-Premise
) I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
was I-Premise
longest I-Premise
for I-Premise
epidermal I-Premise
growth I-Premise
factor I-Premise
receptor I-Premise
gene I-Premise
( I-Premise
EGFR I-Premise
) I-Premise
-mutated I-Premise
patients I-Premise
in I-Premise
the I-Premise
E I-Premise
group I-Premise
, I-Premise
followed I-Premise
by I-Premise
EGFR-mutated I-Premise
patients I-Premise
in I-Premise
V I-Premise
, I-Premise
EGFR I-Premise
wild I-Premise
type I-Premise
in I-Premise
E I-Premise
, I-Premise
and I-Premise
EGFR I-Premise
wild I-Premise
type I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0034 I-Premise
) I-Premise
. I-Premise

Future O
research O
should O
investigate O
ways O
to O
augment O
this O
intervention O
to O
enhance O
its O
benefits O
. O

This O
analysis O
evaluates O
the O
effectiveness O
of O
the O
Improving O
Mood-Promoting O
Access O
to O
Collaborative O
Treatment O
( O
IMPACT O
) O
program O
, O
a O
stepped O
care O
management O
program O
for O
depression O
in O
primary O
care O
patients O
who O
had O
an O
ICD-9 O
cancer O
diagnosis O
. O

The B-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
had I-Premise
a I-Premise
higher I-Premise
mean I-Premise
protein I-Premise
intake I-Premise
( I-Premise
1.1 I-Premise
to I-Premise
1.3 I-Premise
g/kg/day I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
( I-Premise
1.0 I-Premise
to I-Premise
1.1 I-Premise
g/kg/day I-Premise
) I-Premise
( I-Premise
P=0.001 I-Premise
) I-Premise
. I-Premise

DPPE B-Premise
plus I-Premise
DOX I-Premise
was I-Premise
associated I-Premise
with I-Premise
more I-Premise
gastrointestinal I-Premise
and I-Premise
CNS I-Premise
toxicity I-Premise
. I-Premise

Patients O
with O
cancer O
are O
characterized O
by O
a O
profound O
impairment O
of O
glucose O
utilization O
, O
with O
lipids O
being O
the O
preferred O
metabolic O
fuel O
. O

The O
World O
Health O
Organization O
( O
WHO O
) O
guidelines O
for O
the O
treatment O
of O
cancer O
pain O
recommend O
nonopioid O
analgesics O
as O
first-line O
therapy O
, O
so-called O
" O
weak O
" O
analgesics O
combined O
with O
nonopioid O
analgesics O
as O
second-line O
therapy O
, O
and O
so-called O
" O
strong O
" O
opioids O
( O
with O
nonopioid O
analgesics O
) O
only O
as O
third-line O
therapy O
. O

At O
baseline O
after O
surgery O
, O
patient O
functioning O
was O
at O
the O
lowest O
level O
, O
and O
it O
increased O
during O
and O
after O
radiotherapy O
to O
reach O
a O
plateau O
after O
12 O
months O
. O

Manual O
lymphatic O
drainage O
( O
MLD O
) O
and O
compression O
bandage O
combination O
( O
complex O
decongestive O
therapy O
) O
have O
been O
compared O
with O
intermittent O
pneumatic O
compression O
( O
IPC O
) O
plus O
self-lymphatic O
drainage O
( O
SLD O
) O
. O

Each B-Claim
of I-Claim
these I-Claim
regimens I-Claim
produced I-Claim
clinically I-Claim
significant I-Claim
responses I-Claim
, I-Claim
and O
the B-Claim
observed I-Claim
median I-Claim
survival I-Claim
( I-Claim
18.9 I-Claim
months I-Claim
for I-Claim
all I-Claim
71 I-Claim
patients I-Claim
) I-Claim
compares I-Claim
favorably I-Claim
with I-Claim
previously I-Claim
published I-Claim
results I-Claim
, I-Claim
especially I-Claim
in I-Claim
the I-Claim
community I-Claim
setting I-Claim
. I-Claim

The B-Premise
mean I-Premise
quality-adjusted I-Premise
survival I-Premise
was I-Premise
increased I-Premise
by I-Premise
1.8 I-Premise
months I-Premise
in I-Premise
the I-Premise
capecitabine/docetaxel I-Premise
group I-Premise
. I-Premise

Clinical O
, O
treatment O
and O
dosimetric O
variables O
evaluated O
included O
alpha-blocker O
, O
age O
, O
IPSS O
before O
and O
the O
maximum O
after O
treatment O
, O
prostate O
volume O
on O
ultrasonography O
, O
hormonal O
status O
, O
supplemental O
radiotherapy O
, O
isotope O
, O
urethral O
dose O
, O
V O
( O
100/200 O
) O
, O
D90 O
, O
and O
time O
to O
obtaining O
a O
normal O
IPSS O
. O

Radiotherapy B-Claim
was I-Claim
then I-Claim
associated I-Claim
with I-Claim
increased I-Claim
breast I-Claim
symptoms I-Claim
and I-Claim
with I-Claim
greater I-Claim
fatigue I-Claim
but I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
endocrine I-Claim
side-effects I-Claim
. I-Claim

The O
median O
follow-up O
was O
61 O
months O
. O

Patients B-Premise
treated I-Premise
with I-Premise
either I-Premise
docetaxel I-Premise
regimen I-Premise
had I-Premise
more I-Premise
favorable I-Premise
changes I-Premise
in I-Premise
performance I-Premise
status I-Premise
( I-Premise
P=0.065 I-Premise
for I-Premise
DC I-Premise
and I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
and I-Premise
mean I-Premise
weight I-Premise
loss I-Premise
( I-Premise
0.06 I-Premise
kg I-Premise
, I-Premise
gain I-Premise
of I-Premise
0.08 I-Premise
kg I-Premise
, I-Premise
and I-Premise
2.27 I-Premise
kg I-Premise
for I-Premise
DC I-Premise
, I-Premise
DCb I-Premise
, I-Premise
and I-Premise
VC I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
both I-Premise
DC I-Premise
versus I-Premise
VC I-Premise
and I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
. I-Premise

The O
combination O
of O
carboplatin O
and O
paclitaxel O
is O
the O
standard O
of O
care O
for O
the O
treatment O
of O
ovarian O
cancer O
, O
yet O
rates O
of O
recurrence O
and O
death O
remain O
high O
. O

The B-Premise
net I-Premise
balance I-Premise
resulted I-Premise
in I-Premise
$ I-Premise
351 I-Premise
extra I-Premise
cost I-Premise
per I-Premise
patient I-Premise
randomly I-Premise
allocated I-Premise
to I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
. I-Premise

QoL O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
questionnaire O
. O

Results O
indicate O
no O
significant O
differences O
between O
groups O
for O
length O
of O
stay O
( O
t O
= O
.97 O
, O
df O
= O
25 O
, O
p O
> O
.05 O
) O
. O

Patients O
were O
then O
followed O
for O
6 O
months O
and O
evaluated O
for O
quality O
of O
life O
, O
completion O
of O
adjuvant O
treatment O
, O
and O
depressive O
symptoms O
. O

These B-Premise
findings I-Premise
are I-Premise
consistent I-Premise
with I-Premise
evidence I-Premise
that I-Premise
only I-Premise
the I-Premise
combined I-Premise
intervention I-Premise
yielded I-Premise
increases I-Premise
in I-Premise
both I-Premise
exercise I-Premise
and I-Premise
stress I-Premise
management I-Premise
activity I-Premise
. I-Premise

At B-Premise
study I-Premise
completion I-Premise
, I-Premise
participants I-Premise
in I-Premise
the I-Premise
IG I-Premise
were I-Premise
walking I-Premise
twice I-Premise
as I-Premise
far I-Premise
and I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
continued I-Premise
walking I-Premise
or I-Premise
another I-Premise
form I-Premise
of I-Premise
exercise I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
UCG I-Premise
. I-Premise

As O
well O
, O
Etoposide B-Claim
resulted I-Claim
in I-Claim
better I-Claim
physical I-Claim
and I-Claim
psychological I-Claim
subscale I-Claim
scores I-Claim
than I-Claim
radiotherapy I-Claim
, I-Claim
3-drugs I-Claim
and I-Claim
supportive I-Claim
care I-Claim
. I-Claim

At O
6-month O
follow-up O
, O
participants O
were O
mailed O
a O
questionnaire O
that O
assessed O
quality O
of O
life O
, O
self-esteem O
, O
fatigue O
, O
anxiety O
, O
depression O
, O
and O
exercise O
behavior O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
live O
music O
therapy O
on O
quality O
of O
life O
indicators O
, O
amount O
of O
medications O
administered O
and O
length O
of O
stay O
for O
persons O
receiving O
elective O
surgical O
procedures O
of O
the O
brain O
. O

PVI B-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
caused I-Premise
more I-Premise
overall I-Premise
haematological I-Premise
toxicity I-Premise
but I-Premise
CTC I-Premise
grades I-Premise
3/4 I-Premise
was I-Premise
increased I-Premise
only I-Premise
for I-Premise
thrombocytopaenia I-Premise
. I-Premise

Gynecomastia O
, O
breast O
pain O
, O
prostate O
specific O
antigen O
, O
QOL O
, O
sexual O
function O
and O
hormonal O
levels O
were O
assessed O
. O

The O
primary O
outcome O
measures O
were O
dysphagia O
, O
quality O
of O
life O
( O
QL O
) O
6 O
weeks O
following O
treatment O
, O
and O
total O
cost O
of O
treatment O
. O

Intervention O
group O
patients O
received O
the O
Pain O
Education O
Program O
in O
the O
hospital O
, O
and O
3 O
and O
7 O
days O
postdischarge O
by O
telephone O
";" O
this O
was O
done O
by O
nurses O
who O
were O
specially O
trained O
as O
pain O
counselors O
. O

Patients O
in O
control O
group O
( O
31 O
cases O
) O
received O
conventional O
chemotherapy O
, O
whereas O
patients O
in O
the O
combined O
treatment O
group O
( O
41 O
cases O
) O
were O
given O
verapamil O
intraperitoneally O
in O
addition O
to O
chemotherapy O
drugs O
. O

More O
patients O
in O
the O
11 O
day O
group O
had O
respiratory O
symptoms O
at O
baseline O
. O

In O
this O
study O
, O
we O
aimed O
to O
investigate O
the O
efficacy O
of O
BCAA O
granules O
, O
given O
nocturnally O
, O
in O
improving O
QOL O
in O
these O
patients O
. O

Compared B-Premise
with I-Premise
1-year I-Premise
treatment I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
the I-Premise
2-and I-Premise
3-year I-Premise
psychological I-Premise
functions I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Of O
these O
70 O
patients O
, O
46 O
underwent O
pretreatment O
FLIC O
and O
49 O
underwent O
pretreatment O
FACT-L O
. O

Median B-Premise
survival I-Premise
was I-Premise
14.6 I-Premise
months I-Premise
( I-Premise
temozolomide I-Premise
+ I-Premise
radiotherapy I-Premise
) I-Premise
versus I-Premise
12.1 I-Premise
months I-Premise
( I-Premise
radiotherapy I-Premise
alone I-Premise
) I-Premise
. I-Premise

A O
clinical O
trial O
tests O
whether O
a O
psychological O
intervention O
for O
cancer O
patients O
can O
do O
so O
, O
and O
also O
tests O
two O
routes O
to O
achieve O
better O
health O
: O
( O
a O
) O
reducing O
patients O
' O
Emotional O
Distress O
, O
and/or O
( O
b O
) O
enhancing O
their O
functional O
immunity O
. O

Following B-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
was I-Premise
variable I-Premise
, I-Premise
with I-Premise
15 I-Premise
% I-Premise
electing I-Premise
to I-Premise
continue I-Premise
or I-Premise
restart I-Premise
HRT I-Premise
and I-Premise
7 I-Premise
% I-Premise
resuming I-Premise
at I-Premise
follow-up I-Premise
. I-Premise

Based O
on O
this O
safety O
analysis O
, O
the O
next O
step O
of O
study O
recruitment O
was O
continued O
. O

The B-Premise
rate I-Premise
of I-Premise
adverse I-Premise
reactions I-Premise
, I-Premise
including I-Premise
white I-Premise
blood I-Premise
cell I-Premise
reduction I-Premise
, I-Premise
lower I-Premise
platelet I-Premise
count I-Premise
, I-Premise
lower I-Premise
hemoglobin I-Premise
, I-Premise
and I-Premise
hair I-Premise
loss I-Premise
in I-Premise
the I-Premise
PP I-Premise
group I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
GP I-Premise
group I-Premise
. I-Premise

Overall B-Premise
, I-Premise
patients I-Premise
treated I-Premise
with I-Premise
either I-Premise
docetaxel-containing I-Premise
regimen I-Premise
had I-Premise
better I-Premise
QoL I-Premise
than I-Premise
VC-treated I-Premise
patients I-Premise
( I-Premise
LCSS I-Premise
global I-Premise
item I-Premise
" I-Premise
QoL I-Premise
today I-Premise
" I-Premise
: I-Premise
P=0.064 I-Premise
for I-Premise
DC I-Premise
and I-Premise
P=0.016 I-Premise
for I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
";" I-Premise
EQ-5D I-Premise
global I-Premise
item I-Premise
" I-Premise
health I-Premise
state I-Premise
today I-Premise
" I-Premise
: I-Premise
P=0.016 I-Premise
for I-Premise
DC I-Premise
and I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
. I-Premise

Food B-Premise
intake I-Premise
improved I-Premise
more I-Premise
rapidly I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
, I-Premise
but B-Premise
long-term I-Premise
relief I-Premise
of I-Premise
obstructive I-Premise
symptoms I-Premise
was I-Premise
better I-Premise
after I-Premise
GJJ I-Premise
. I-Premise

Recruited O
were O
167 O
solid O
tumor O
children O
patients O
at O
Department O
of O
Tumor O
, O
Beijing O
Children O
's O
Hospital O
. O

Psychological B-Premise
quality I-Premise
of I-Premise
life I-Premise
also I-Premise
improved I-Premise
more I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
from I-Premise
49.6 I-Premise
to I-Premise
61.2 I-Premise
vs. I-Premise
50.1 I-Premise
to I-Premise
51.5 I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,84 I-Premise
) I-Premise
) I-Premise
= I-Premise
10.9 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

Younger B-Premise
patients I-Premise
( I-Premise
< I-Premise
40 I-Premise
years I-Premise
) I-Premise
who I-Premise
received I-Premise
goserelin I-Premise
alone I-Premise
returned I-Premise
to I-Premise
their I-Premise
premenopausal I-Premise
status I-Premise
at I-Premise
6 I-Premise
months I-Premise
after I-Premise
the I-Premise
cessation I-Premise
of I-Premise
therapy I-Premise
, I-Premise
while I-Premise
those I-Premise
who I-Premise
received I-Premise
CMF I-Premise
showed I-Premise
marginal I-Premise
changes I-Premise
from I-Premise
their I-Premise
baseline I-Premise
hot I-Premise
flashes I-Premise
scores I-Premise
. I-Premise

We O
enrolled O
1669 O
eligible O
patients O
, O
382 O
( O
23 O
% O
) O
with O
ER-negative O
tumors O
, O
1217 O
( O
73 O
% O
) O
with O
ER-positive O
tumors O
, O
and O
70 O
( O
4 O
% O
) O
with O
unknown O
ER O
status O
. O

Main O
exclusion O
criteria O
were O
brain O
or O
bone O
metastases O
. O

This O
Phase O
II O
, O
open-label O
study O
was O
conducted O
to O
confirm O
the O
activity O
of O
SGN-15 O
plus O
docetaxel O
in O
previously O
treated O
NSCLC O
patients O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
effects I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
mood I-Premise
, I-Premise
QOL I-Premise
or I-Premise
healthcare I-Premise
utilisation I-Premise
. I-Premise

Eighty O
participants O
completed O
all O
follow-ups O
. O

Ninety-four O
patients O
received O
PB O
, O
and O
93 O
received O
paclitaxel/bevacizumab/gemcitabine O
( O
PB+G O
) O
. O

The O
Programme O
Etude O
Rein O
Cytokines O
( O
PERCY O
) O
Quattro O
trial O
was O
designed O
to O
evaluate O
both O
cytokines O
for O
their O
survival O
benefit O
to O
intermediate O
prognosis O
patients O
, O
who O
represent O
the O
majority O
of O
candidates O
for O
these O
treatments O
. O

There O
were O
532 O
eligible O
patients O
( O
266 O
marimastat O
and O
266 O
placebo O
) O
. O

and O
intravenous O
( O
i.v O
. O
) O

Response B-Claim
to I-Claim
gemcitabine I-Claim
treatment I-Claim
in I-Claim
APC I-Claim
is I-Claim
not I-Claim
associated I-Claim
with I-Claim
appreciable I-Claim
improvement I-Claim
of I-Claim
global I-Claim
HRQOL I-Claim
. I-Claim

Two-year B-Premise
survival I-Premise
rate I-Premise
was I-Premise
18 I-Premise
% I-Premise
with I-Premise
DCF I-Premise
and I-Premise
9 I-Premise
% I-Premise
with I-Premise
CF I-Premise
. I-Premise

Increased B-Premise
appetite I-Premise
was I-Premise
reported I-Premise
by I-Premise
73 I-Premise
% I-Premise
, I-Premise
58 I-Premise
% I-Premise
, I-Premise
and I-Premise
69 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
CE I-Premise
, I-Premise
THC I-Premise
, I-Premise
or I-Premise
PL I-Premise
, I-Premise
respectively I-Premise
. I-Premise

This O
study O
sought O
to O
evaluate O
effectiveness O
of O
autologous O
dendritic O
cell O
vaccine O
( O
immunotherapy O
) O
for O
glioblastoma O
multiforme O
( O
GBM O
) O
. O

The B-Premise
unadjusted I-Premise
relative I-Premise
risk I-Premise
for I-Premise
mortality I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
group I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
was I-Premise
1.11 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.76-1.63 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.59 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
amount I-Premise
of I-Premise
residual I-Premise
tumor I-Premise
tissue I-Premise
was I-Premise
28.9 I-Premise
% I-Premise
for I-Premise
standard I-Premise
surgery I-Premise
( I-Premise
SS I-Premise
) I-Premise
and I-Premise
13.8 I-Premise
% I-Premise
for I-Premise
surgery I-Premise
involving I-Premise
neuronavigation I-Premise
( I-Premise
SN I-Premise
) I-Premise
. I-Premise

The O
benefits O
of O
the O
intervention O
were O
evaluated O
using O
the O
Zung O
Self-rating O
Depression O
Scale O
( O
SDS O
) O
to O
measure O
depression O
, O
the O
Self-rating O
Anxiety O
Scale O
( O
SAS O
) O
to O
assess O
anxiety O
, O
and O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire-Core O
30 O
( O
EORTC O
QLQ-C30 O
) O
to O
survey O
health-related O
QOL O
. O

Overall B-Premise
objective I-Premise
response I-Premise
( I-Premise
OR I-Premise
) I-Premise
rates I-Premise
were I-Premise
higher I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
EXE I-Premise
than I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
MA I-Premise
( I-Premise
15.0 I-Premise
% I-Premise
v I-Premise
12.4 I-Premise
% I-Premise
) I-Premise
";" I-Premise
a B-Premise
similar I-Premise
trend I-Premise
was I-Premise
noted I-Premise
in I-Premise
patients I-Premise
with I-Premise
visceral I-Premise
metastases I-Premise
( I-Premise
13.5 I-Premise
% I-Premise
v I-Premise
10.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Eight B-Premise
of I-Premise
the I-Premise
17 I-Premise
quality-of-life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
variables I-Premise
assessed I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
of I-Premise
more I-Premise
than I-Premise
10 I-Premise
% I-Premise
between I-Premise
baseline I-Premise
and I-Premise
the I-Premise
start I-Premise
of I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
treatment I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
better I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
three I-Premise
cycles I-Premise
";" I-Premise
no B-Premise
differences I-Premise
were I-Premise
detected I-Premise
between I-Premise
3 I-Premise
and I-Premise
5 I-Premise
days I-Premise
of I-Premise
treatment I-Premise
. I-Premise

Serum O
CA125 O
concentration O
often O
rises O
several O
months O
before O
clinical O
or O
symptomatic O
relapse O
in O
women O
with O
ovarian O
cancer O
. O

Without B-Premise
ADT I-Premise
testosterone I-Premise
remained I-Premise
at I-Premise
castrate I-Premise
level I-Premise
for I-Premise
4 I-Premise
months I-Premise
. I-Premise

Swallowing B-Premise
and I-Premise
coughing I-Premise
problems I-Premise
decreased I-Premise
more I-Premise
in I-Premise
the I-Premise
TPF I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
PF I-Premise
arm I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
cycle I-Premise
2 I-Premise
, I-Premise
but B-Premise
to I-Premise
a I-Premise
limited I-Premise
extent I-Premise
. I-Premise

Cross-sectional B-Premise
analyses I-Premise
( I-Premise
corrected I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
) I-Premise
identified I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
that I-Premise
favored I-Premise
orchiectomy I-Premise
plus I-Premise
placebo I-Premise
for I-Premise
two I-Premise
of I-Premise
the I-Premise
five I-Premise
primary I-Premise
QOL I-Premise
parameters I-Premise
as I-Premise
follows I-Premise
: I-Premise
patients I-Premise
receiving I-Premise
flutamide I-Premise
reported I-Premise
more I-Premise
diarrhea I-Premise
at I-Premise
3 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
and I-Premise
worse I-Premise
emotional I-Premise
functioning I-Premise
at I-Premise
3 I-Premise
and I-Premise
6 I-Premise
months I-Premise
( I-Premise
both I-Premise
P I-Premise
< I-Premise
.003 I-Premise
) I-Premise
. I-Premise

We O
performed O
a O
randomized O
, O
double-blind O
, O
28-day O
trial O
of O
melatonin O
20 O
mg O
versus O
placebo O
in O
patients O
with O
advanced O
lung O
or O
GI O
cancer O
, O
appetite O
scores O
≥ O
4 O
on O
a O
0 O
to O
10 O
scale O
( O
10 O
= O
worst O
appetite O
) O
, O
and O
history O
of O
weight O
loss O
≥ O
5 O
% O
. O

Physician O
and O
nurse O
ratings O
were O
closer O
to O
patients O
' O
ratings O
of O
pain O
for O
trained O
versus O
nutrition O
groups O
( O
P=.04 O
and O
< O
.001 O
, O
respectively O
) O
. O

Short-term B-Claim
postoperative I-Claim
morbidity I-Claim
was I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
groups I-Claim
. I-Claim

There B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
improved I-Premise
global I-Premise
HRQOL I-Premise
during I-Premise
the I-Premise
treatment I-Premise
period I-Premise
. I-Premise

Five O
years O
later O
, O
these O
190 O
men O
underwent O
HRQOL O
evaluation O
by O
using O
the O
cancer-specific O
50-item O
Expanded O
Prostate O
Cancer O
Index O
Composite O
, O
the O
Short O
Form O
12 O
Physical O
Component O
Score O
, O
and O
Short O
Form O
12 O
Mental O
Component O
Score O
. O

To O
compare O
protracted O
venous O
infusion O
( O
PVI O
) O
5-fluorouracil O
( O
5-FU O
) O
with O
and O
without O
mitomycin O
C O
( O
MMC O
) O
in O
a O
prospectively O
randomised O
study O
and O
analyse O
for O
tumour O
response O
, O
survival O
, O
toxicity O
and O
quality O
of O
life O
( O
QL O
) O
. O

The O
TAX O
327 O
study O
compared O
docetaxel O
administered O
every O
3 O
weeks O
( O
D3 O
) O
, O
weekly O
docetaxel O
( O
D1 O
) O
, O
and O
mitoxantrone O
( O
M O
) O
, O
each O
with O
prednisone O
( O
P O
) O
, O
in O
1,006 O
men O
with O
metastatic O
hormone-resistant O
prostate O
cancer O
( O
HRPC O
) O
. O

In B-Premise
terms I-Premise
of I-Premise
pulmonary I-Premise
function I-Premise
, I-Premise
dyspnoic I-Premise
and I-Premise
coughing I-Premise
symptoms I-Premise
were I-Premise
significantly I-Premise
worsened I-Premise
3 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
( I-Premise
P I-Premise
= I-Premise
0.024 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.036 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
whereas I-Premise
symptoms I-Premise
in I-Premise
the I-Premise
CRT I-Premise
group I-Premise
progressively I-Premise
deteriorated I-Premise
over I-Premise
time I-Premise
. I-Premise

Patients O
completed O
QL O
indicators O
at O
baseline O
and O
at O
1 O
, O
3 O
, O
5 O
, O
7 O
, O
9 O
, O
and O
11 O
months O
. O

Mean B-Premise
scores I-Premise
were I-Premise
generally I-Premise
improved I-Premise
by I-Premise
the I-Premise
end-of-treatment I-Premise
assessment I-Premise
vs. I-Premise
baseline I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Questionnaire O
compliance O
was O
94 O
% O
at O
baseline O
, O
but O
it O
declined O
differentially O
( O
67 O
% O
v O
47 O
% O
for O
cetuximab O
v O
BSC O
at O
16 O
weeks O
) O
. O

Five O
, O
five O
, O
and O
four O
patients O
, O
treated O
with O
oral O
morphine O
, O
transdermal O
fentanyl O
, O
and O
oral O
methadone O
, O
respectively O
, O
required O
opioid O
switching O
. O

At B-Premise
6 I-Premise
months I-Premise
and I-Premise
2 I-Premise
years I-Premise
, I-Premise
using I-Premise
non-responder I-Premise
analyses I-Premise
, I-Premise
ACR I-Premise
responses I-Premise
in I-Premise
abatacept-treated I-Premise
patients I-Premise
were I-Premise
: I-Premise
ACR I-Premise
20 I-Premise
, I-Premise
59.4 I-Premise
% I-Premise
and I-Premise
56.2 I-Premise
% I-Premise
";" I-Premise
ACR I-Premise
50 I-Premise
, I-Premise
23.5 I-Premise
% I-Premise
and I-Premise
33.2 I-Premise
% I-Premise
";" I-Premise
ACR I-Premise
70 I-Premise
, I-Premise
11.5 I-Premise
% I-Premise
and I-Premise
16.1 I-Premise
% I-Premise
";" I-Premise
HAQ-DI I-Premise
responses I-Premise
were I-Premise
54.4 I-Premise
% I-Premise
and I-Premise
47.9 I-Premise
% I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
in I-Premise
the I-Premise
patients I-Premise
receiving I-Premise
induction I-Premise
chemotherapy I-Premise
only I-Premise
was I-Premise
8.9 I-Premise
months I-Premise
. I-Premise

In B-Claim
conclusion I-Claim
, I-Claim
palliative I-Claim
chemotherapy I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
vinorelbine I-Claim
beyond I-Claim
three I-Claim
courses I-Claim
conveys I-Claim
no I-Claim
survival I-Claim
or I-Claim
consistent I-Claim
QoL I-Claim
benefits I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

To O
examine O
the O
effect O
of O
a O
progressive O
upper-body O
exercise O
program O
on O
lymphedema O
secondary O
to O
breast O
cancer O
treatment O
. O

The B-Claim
advantages I-Claim
of I-Claim
a I-Claim
long-lasting I-Claim
improved I-Claim
body I-Claim
image I-Claim
and I-Claim
cosmesis I-Claim
for I-Claim
this I-Claim
relatively I-Claim
young I-Claim
patient I-Claim
population I-Claim
may I-Claim
compensate I-Claim
for I-Claim
the I-Claim
longer I-Claim
operating I-Claim
times I-Claim
and I-Claim
higher I-Claim
costs I-Claim
, I-Claim
particularly I-Claim
for I-Claim
women I-Claim
. I-Claim

The B-Premise
incidence I-Premise
of I-Premise
WHO I-Premise
grade I-Premise
3 I-Premise
or I-Premise
4 I-Premise
anemia I-Premise
, I-Premise
neutropenia I-Premise
and I-Premise
thrombocytopenia I-Premise
was I-Premise
29 I-Premise
, I-Premise
44 I-Premise
and I-Premise
22 I-Premise
% I-Premise
( I-Premise
GE I-Premise
group I-Premise
) I-Premise
, I-Premise
and I-Premise
28 I-Premise
, I-Premise
49 I-Premise
and I-Premise
23 I-Premise
% I-Premise
( I-Premise
GP I-Premise
group I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.75 I-Premise
, I-Premise
0.95 I-Premise
and I-Premise
0.87 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Claim
16-week I-Claim
regimen I-Claim
should I-Claim
not I-Claim
be I-Claim
used I-Claim
instead I-Claim
of I-Claim
a I-Claim
standard-dose I-Claim
regimen I-Claim
without I-Claim
careful I-Claim
consideration I-Claim
of I-Claim
the I-Claim
16-week I-Claim
regimen I-Claim
's I-Claim
pros I-Claim
and I-Claim
cons I-Claim
, I-Claim
which I-Claim
include I-Claim
its I-Claim
complicated I-Claim
schedule I-Claim
. I-Claim

The O
distribution O
of O
bulky O
N2 O
disease O
was O
uniform O
among O
the O
treatment O
arms O
. O

Assessments O
were O
done O
at O
baseline O
, O
9 O
weeks O
, O
and O
26 O
weeks O
after O
randomisation O
. O

QOL B-Premise
, I-Premise
except I-Premise
for I-Premise
symptoms I-Premise
of I-Premise
sensory I-Premise
neuropathy I-Premise
and I-Premise
hearing I-Premise
loss I-Premise
, I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
chemotherapy I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
by I-Premise
9 I-Premise
months I-Premise
. I-Premise

Patients O
were O
randomly O
assigned O
in O
a O
2:1 O
ratio O
to O
undergo O
either O
uterine-artery O
embolization O
or O
surgery O
, O
with O
106 O
patients O
undergoing O
embolization O
and O
51 O
undergoing O
surgery O
( O
43 O
hysterectomies O
and O
8 O
myomectomies O
) O
. O

Safety O
was O
also O
assessed O
. O

This O
randomized O
trial O
demonstrates O
that O
ATP B-Claim
has I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
weight I-Claim
, I-Claim
muscle I-Claim
strength I-Claim
, I-Claim
and I-Claim
QOL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Secondary O
outcomes O
included O
additional O
QOL O
measures O
, O
patient O
satisfaction O
, O
safety O
and O
health O
economics O
. O

All O
P O
values O
are O
two-sided O
. O

The O
primary O
outcome O
measures O
were O
arm O
and O
shoulder O
morbidity O
and O
quality O
of O
life O
. O

In B-Premise
grade I-Premise
IV I-Premise
the I-Premise
corresponding I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
12.3 I-Premise
( I-Premise
2.1-89.2 I-Premise
) I-Premise
and I-Premise
10.3 I-Premise
( I-Premise
0.3-91.7+ I-Premise
) I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The O
primary O
endpoint O
was O
changes O
in O
oral O
calorie O
intake O
, O
and O
the O
secondary O
endpoints O
were O
chemotherapy-related O
adverse O
events O
";" O
appetite O
visual O
analog O
scale O
( O
VAS O
) O
scores O
";" O
changes O
in O
gastrointestinal O
hormones O
and O
nutritional O
status O
, O
including O
rapid O
turnover O
proteins O
, O
and O
quality O
of O
life O
( O
QoL O
) O
estimated O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QoL O
core O
questionnaire O
( O
QLQ-C30 O
) O
. O

The B-Premise
change I-Premise
in I-Premise
physical I-Premise
function I-Premise
( I-Premise
muscle I-Premise
strength I-Premise
∼11 I-Premise
% I-Premise
";" I-Premise
submaximal I-Premise
aerobic I-Premise
exercise I-Premise
capacity I-Premise
∼5 I-Premise
% I-Premise
and I-Premise
ambulation I-Premise
∼12 I-Premise
% I-Premise
) I-Premise
, I-Premise
physical I-Premise
activity I-Premise
level I-Premise
( I-Premise
∼24 I-Premise
% I-Premise
) I-Premise
and I-Premise
lean I-Premise
mass I-Premise
( I-Premise
∼3 I-Premise
% I-Premise
) I-Premise
differed I-Premise
significantly I-Premise
between I-Premise
groups I-Premise
following I-Premise
the I-Premise
intervention I-Premise
, I-Premise
with I-Premise
favorable I-Premise
changes I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
. I-Premise

QOL O
was O
assessed O
by O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
and O
the O
lung O
cancer O
module O
QLQ-LC13 O
. O

As B-Premise
with I-Premise
previously I-Premise
published I-Premise
results I-Premise
at I-Premise
2 I-Premise
years I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
of I-Premise
the I-Premise
FACT-B I-Premise
, I-Premise
the I-Premise
primary I-Premise
endpoint I-Premise
of I-Premise
the I-Premise
study I-Premise
, I-Premise
between I-Premise
treatments I-Premise
at I-Premise
5 I-Premise
years I-Premise
. I-Premise

The B-Claim
effects I-Claim
of I-Claim
Pemetrexed I-Claim
and I-Claim
Gefitinib I-Claim
as I-Claim
second I-Claim
line I-Claim
therapy I-Claim
were I-Claim
similar I-Claim
, I-Claim
although B-Premise
with I-Premise
different I-Premise
AEs I-Premise
. I-Premise

Both B-Premise
brief I-Premise
and I-Premise
extensive I-Premise
programs I-Premise
had I-Premise
positive I-Premise
outcomes I-Premise
for I-Premise
patient-caregiver I-Premise
dyads I-Premise
, I-Premise
but B-Premise
few I-Premise
sustained I-Premise
effects I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
42 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
( I-Premise
11 I-Premise
months I-Premise
v I-Premise
9.1 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
and I-Premise
TFS I-Premise
( I-Premise
15 I-Premise
months I-Premise
v I-Premise
11 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
were I-Premise
superior I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
. I-Premise

The B-Premise
results I-Premise
of I-Premise
both I-Premise
the I-Premise
FLIC I-Premise
and I-Premise
FACT-L I-Premise
demonstrated I-Premise
significantly I-Premise
lower I-Premise
scores I-Premise
corresponding I-Premise
to I-Premise
lower I-Premise
KPS I-Premise
values I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.016 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Local B-Premise
recurrence I-Premise
was I-Premise
2/74 I-Premise
( I-Premise
stage I-Premise
III I-Premise
";" I-Premise
2.7 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
1/92 I-Premise
( I-Premise
stage I-Premise
II I-Premise
";" I-Premise
1.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Consistent O
results O
are O
observed O
across O
subgroups O
of O
patients O
. O

Patients O
were O
eligible O
if O
they O
were O
aged O
> O
OR= O
70 O
years O
, O
had O
stage O
IIIB O
( O
with O
pleural O
effusion O
) O
or O
stage O
IV O
NSCLC O
, O
had O
a O
performance O
status O
of O
0/1 O
, O
had O
not O
previously O
received O
chemotherapy O
, O
and O
had O
normal O
organ O
function O
. O

All O
complications O
were O
recorded O
, O
and O
these O
preoperative O
assessments O
were O
repeated O
at O
4 O
months O
. O

Cyclooxygenase-2 B-Claim
( I-Claim
COX-2 I-Claim
) I-Claim
inhibitors I-Claim
have I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
effective I-Claim
in I-Claim
chemoprevention I-Claim
in I-Claim
animal I-Claim
and I-Claim
clinical I-Claim
studies I-Claim
. I-Claim

